LifeStance Health Group, Inc.

and I will be a conference operator today. At this time, I would like to welcome everyone to the live stance held first quarter 2024 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, Press star one again. I would now like to turn the call over to Monica Prokoski, Vice President of Investor Relations. Please go ahead.

Thank you, Operator. Good morning, everyone, and welcome to LifeStamps Health First Quarter 2024 Earnings Conference Call. I'm Monica Prokoski, Vice President of Investor Relations. Joining me today are Ken Burdick, Chief Executive Officer, Dave Borden, Chief Financial Officer, and Danish Koreshi, Chief Operating Officer. We issued the earnings release and presentation before the market opened this morning. Those are available on the investor relations section of our website, investor.lifedance.com. In addition, a replay of this conference call will be available following the call. Before turning the call over to management for their prepared remarks, Please direct your attention to the disclaimers about forward-looking statements included in the earnings press release and SEC filings. Today's remarks contain forward-looking statements, including statements about our financial performance outlook, business model, and strategy. Those statements involve risks, uncertainties, and other factors, as noted in our periodic filings with the SEC, that could cause actual results to differ materially. In addition, please note that we report results using non-GAAP financial measures, which we believe provide additional information for investors to help facilitate comparison of current and past performance. A reconciliation to the most directly comparable gap measures is included in the earnings press release tables and presentation appendix. Unless otherwise noted, all results are compared to the comparable period in the prior year. At this time, I'll turn the call over to Ken Burdick, CEO of Livestam.

Ken? Thanks, Monica. And thank you all for joining us today. In the first quarter, we once again beat on all our guided metrics, making this the sixth consecutive quarter that LifeStance has met or exceeded expectations. We delivered strong financial performance with revenue growth of 19% to $300 million and adjusted EBITDA up 174% to $28 million. We are also raising full-year adjusted EBITDA guidance based on the strength of the quarter. Our clinician value proposition continues to resonate with 221 net clinician ads in the quarter, representing 15% entirely organic growth in our clinician base. Our patient experience continues to receive outstanding scores with a patient net promoter score of 84, and average Google reviews across life stance centers at 4.5 out of 5 stars. Before covering our strategic and operational highlights, I would like to share the news that Danish has reached the difficult decision to leave life stance. Knowing this was not an easy decision, I'd like to give Danish the opportunity to directly share his thoughts with all of you.